Therapeutic Targeting of miR-21 Restores SASH1 and Sensitizes HBV-HCC to Sorafenib
Abstract
Simple Summary Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) frequently develops resistance to sorafenib, limiting treatment efficacy. We showed that miR-21 is highly expressed in HBV-positive HCC and directly suppresses the tumor suppressor SASH1. Loss of SASH1 enhances HBx-driven oncogenic signaling and reduces sorafenib-induced apoptosis. miR-21 inhibition restores the SASH1 expression and significantly improves sorafenib response in in vitro and in vivo models. These findings suggested that targeting miR-21 may represent a promising strategy to overcome sorafenib resistance in HBV-associated HCC.
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.